![]() Hepatic Impairment: No initial dosage adjustment is required for patients with mild or moderate liver insufficiency. Titrate slowly in patients with severe renal impairment. Renal Impairment: No initial dosage adjustment is required for patients with mild or moderate renal impairment. COVERT may be administered with other antihypertensive agents.Įlderly Patients: Because of decreased clearance of amlodipine, therapy should be initiated at 2.5 mg.COVERT may be administered with or without food.The dosage can be increased after 1 to 2 weeks of therapy to a maximum of one 320/10 mg tablet once daily as needed to control blood pressure. The majority of the antihypertensive effect is attained within 2 weeks after initiation of therapy or a change in dose. Dosage & Administration General considerations Patients with stage (2) hypertension (moderate to severe) are at a relatively higher risk for cardiovascular events, kidney failure and vision problems, so prompt treatment is clinically relevant. The choice of COVERT as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the lowest dose of COVERT. As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.In patients not adequately controlled on monotherapy.Excipients: S.Q for one film-coated tablet.ĬOVERT is indicated for the treatment of hypertension:. ![]() COVERT is an antihypertensive drug which is a fixed combination of amlodipine (as the besylate salt) and valsartan.Īmlodipine is a dihydropyridine calcium channel blocker, valsartan is a nonpeptide, orally active, and specific angiotensin II antagonist acting on the AT 1 receptor subtype.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |